Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | RNA recognition motif domain containing protein | 0.0061 | 1 | 1 |
Brugia malayi | TAR-binding protein | 0.0061 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0061 | 1 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.0061 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0061 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0061 | 1 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0061 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0048 | 0.5069 | 0.5069 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0048 | 0.5069 | 0.5069 |
Schistosoma mansoni | tar DNA-binding protein | 0.0061 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 0 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 4.42 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 5.23 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 5.62 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 28 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
Inhibition (functional) | = 63 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 96 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition frequency index (IFI) (functional) | = 6.12 | Inhibition Frequency Index (IFI) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 0 % | Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 28 % | Percent inhibition of HepG2 growth (at 10 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 63 % | Percent inhibition of P. falciparum Dd2 growth (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 96 % | Percent inhibition of P. falciparum 3D7 growth (at 2 uM) | GSK. | 20485427 |
XC50 (functional) | = 6.06 | XC50 determination of P. falciparum 3D7 growth | GSK. | 20485427 |
XC50 (functional) | = 0.87447 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.